First quarter 2026 gross profit increased 71.9% compared to the first quarter of 2025
First quarter same-store sales were up 7.3%, and same-store prescription sales were up 7.2%, both compared to the first quarter of 2025
SASKATOON, Saskatchewan, June 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. ("PharmaCorp" or the "Corporation") (TSXV:PCRX) a Canadian pharmacy services and consolidation platform, today reported its financial results for the first quarter ended March 31, 2026.
"We further scaled our business in the first quarter by successfully integrating our recent pharmacy acquisitions, and advancing our unique and expanding pipeline of additional M&A opportunities," said Alan Simpson, Executive Chairman of PharmaCorp. "We believe our growth demonstrates that our focus on preserving the legacy and community role of independent pharmacies, coupled with our operational, financial, and strategic expertise, is resonating within the industry in Canada."
First Quarter 2026 Financial Highlights
First quarter 2026 revenue of $7.2 million compared to $4.0 million in the first quarter of 2025, representing an increase of 79.4%.
First quarter 2026 gross profit of $2.8 million compared to $1.6 million in the first quarter of 2025 with margins of 38.8% and 40.5% respectively.
First quarter 2026 Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis)1 , a Non-IFRS Financial Measure, of $0.9 million compared to $0.7 million in the first quarter of 2025, representing an increase of 30.1%.
Revenues, gross profit and Adjusted EBITDA, a Non-IFRS Financial Measure, were higher year-over-year due to increases in prescription volumes and front-of-store sales, and owning more pharmacies in the first quarter of 2026 versus the prior-year period. These metrics were slightly lower compared to the fourth quarter of 2025 due to seasonality factors such as peak season for cold and flu, and COVID-19 vaccination ramp-ups that tend to strengthen the fourth quarter across the industry.
Same-store sales, a Supplementary Financial Measure, increased 7.3% year-over-year compared to the first quarter of 2025, reflecting continued organic growth across PharmaCorp's pharmacy network.
Same-store prescription sales, a Supplementary Financial Measure, increase of 7.2% year-over-year compared to the first quarter of 2025, demonstrating sustained patient engagement and activity across the network.
First quarter 2026 net loss of $0.09 million compared to net income of $0.22 million in the first quarter of 2025. Net loss increased year-over-year for the quarterly period due to additional employee compensation in the first quarter of 2026 compared to 2025, along with a shift in annual payments in 2025 compared to 2026.
As of March 31, 2026, the Corporation had cash of $23.4 million compared to $25.9 million at December 31, 2025.
Operational Highlights
Continued the successful integration of the three community pharmacy businesses acquired in October 2025. The pharmacies performed as expected in the first quarter of 2026 and the integration is proceeding as anticipated.
Subsequent to quarter end, announced that it entered into definitive share purchase agreements to acquire a 100% interest in eight PharmaChoice Canada bannered pharmacies located in Eastern Canada. This acquisition is on track to close towards the end of June 2026.
Subsequent to quarter end, announced the completion of its acquisition of the prescription files, patient records and related operational data of a pharmacy located in the same community as one of PharmaCorp's existing PharmaChoice-bannered pharmacies in Western Canada.
Subsequent to quarter end, announced it entered into a definitive share purchase agreement to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy located in Ontario.
